Jianghua Tu

The paper develops RSPO2-based peptibody-drug conjugates that target LGR4/5/6 receptors, showing potent anti-tumor activity in colorectal cancer and neuroblastoma models.

This study develops and tests a camptothecin analog conjugate targeting LGR4/5/6 in CRC models, showing potent anti-tumor activity with minimal toxicity.

The paper shows that ZNRF3/RNF43 ubiquitinates and degrades EGFR, and their loss increases EGFR signaling, promoting cancer growth.